Talking Points

C. Michael Gibson and Wan Azman Wan Ahmad discuss a sirolimus-versus a paclitaxel-coated balloon in de novo coronary lesions.

C. Michael Gibson and Stefan Anker discuss the effects of empagliflozin on CV death and HF hospitalizations in patients with HFpEF, with and without diabetes.

C. Michael Gibson and Matthias Götberg review 5-year findings after iFR- versus FFR-guided PCI.

Renato Lopes and C. Michael Gibson discuss PRONOUNCE comparing the cardiovascular safety of degarelix vs. leuprolide in patients with advanced prostate cancer and CVD.

Desai and Anahita Dua discuss highlights from a CME program on reducing thrombosis risks in patients with PAD post-revascularization. Claim credit: https://bit.ly/3QTpBt6. Supported by an educational grant from Janssen Scientific Affairs, LLC.

C. Michael Gibson and Steffen Desch discuss whether immediate angiography is warranted after out-of-hospital cardiac arrest.

C. Michael Gibson and David Kandzari discuss PCI outcomes among patients at prohibitive risk for CABG.

C. Michael Gibson and Marco Valgimigli discuss dual antiplatelet therapy after coronary stenting in high-bleeding-risk patients.

C. Michael Gibson, Haibo Jia, and Jingbo Hou discuss whether OCT guidance could cut stent use in STEMI without plaque rupture.

C. Michael Gibson and Douglas Mann discuss sacubitril/valsartan in patients with advanced HFrEF.

C. Michael Gibson and Pavel Osmancik review 3-year results with LAA closure versus a DOAC for patients with atrial fibrillation.

C. Michael Gibson and Pieter C. Smits review outcomes in high-bleeding-risk patients also at high risk for thrombotic events who were randomized to abbreviated DAPT.

C. Michael Gibson discusses aspirin dosing and long-term effectivness with Schuyler Jones and Greg Merritt.

C. Michael Gibson and Kreton Mavromatis discuss how completeness of revascularization impacts quality of life in stable ischemic heart disease patients.

C. Michael Gibson and Steven Nissen discuss the link between omega-3 fatty acid levels and MACE in patients with high cardiovascular risk.

C. Michael Gibson and Robert Galea discuss Amulet versus Watchman for LAA closure.

C. Michael Gibson and Carolyn Lam discuss key updates to the European heart failure guidelines and how best to initiate medications to optimize outcomes.

C. Michael Gibson, Jean-Philippe Collet, and Gilles Montalescot and discuss apixiban after TAVI in the Atlantis trial.

C. Michael Gibson and Firas Zahr discuss 30-day outcomes following transfemoral transseptal TMVR.

C. Michael Gibson and Bruno Scheller discuss 1-year outcomes of two parallel RCTs.